Results 161 to 170 of about 8,055 (251)

Incretin‐Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice

Obesity Reviews, EarlyView.
ABSTRACT Introduction Pregnancy concurrent with incretin‐based medications is contraindicated due to unknown risk of teratogenicity, as is breastfeeding. The aim of this systematic scoping review was to investigate potential risks and benefits of incretin‐based medications in relation to preconception, pregnancy, and postnatal health, and to propose ...
Kate Maslin, Jill Shawe, Sinead Blowers, Michael Ceulemans, Kathryn Hart, Sam Schoenmakers, Amihai Rottenstreich, Heather Hopper, Mojca Jensterle, Angela C. Flynn, Sarah Siegelaar, Annick Bogaerts, Isy Douek, Nicola Heslehurst, Dries Ceulemans, Tricia Tan, Johnathan Pinkney, Martin Whyte, Shahrad Taheri, Roland Devlieger   +19 more
wiley   +1 more source

Targeting Overweight and Obesity Phenotypes for Secondary Prevention of Cardiovascular Disease: A Call to Action for the Middle East and Beyond

Obesity Reviews, EarlyView.
ABSTRACT Although there are conflicting clinical data on the efficacy of weight reduction in reducing secondary events in patients with comorbid overweight and obesity (OAO) and cardiovascular disease (CVD), there is excellent epidemiological and biological evidence of a cause–effect relationship between OAO, CVD, and other systemic complications ...
Wael Almahmeed, Juan S. Barajas‐Gamboa, Mohammad Zubaid, Ebaa Al Ozairi, Abdullah Shehab, Khalid Al‐Rasadi, Charbel Abi Khalil, Noor Al Busaidi, Fahad Al Sindi, Zuhier Awan, Tomader Ali, Khaldoon Al‐Humood, Fatheya Al Awadi, Mohammed Al Hadad, Manal Al Kindi, Khalid Al Habib, Khalid Al Waili, Maryam Alsaeed, Adel Tash, Hani Sabbour   +19 more
wiley   +1 more source

Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis. [PDF]

Clin Cardiol
Khalil I, Hossain MI, Akter MM, Wahid F, Khalid AA, Promi SA, Sayed MA, Rahman MT, Sarker P.   +8 more
europepmc   +1 more source

Rethinking Global Obesity Guidelines: Integrating Evidence, Equity and Precision (2014–2026)

Obesity Reviews, EarlyView.
Challenges and evidence in obesity guidelines. ABSTRACT Obesity remains a global health crisis characterized by substantial heterogeneity in diagnosis, management, and policy implementation. Although numerous national and international clinical practice guidelines have been published over the past decade, their translation into evidence‐based and ...
Rosero‐Revelo Ricardo, Tamayo Mateo, Henao Diana, Juan P. Polanco, Cortés David, Juan C. Alba, Giha Valeria, Camargo Camilo, Hernández Eder, Correa Ricardo, Nassar Ricardo, Cabandugama Peminda, Marcio L. Griebeler, Burguera Bartolome   +13 more
wiley   +1 more source

A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors. [PDF]

Cureus
Iqbal S, Javed F, Oyibo SO.
europepmc   +1 more source

Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan

Obesity Reviews, EarlyView.
ABSTRACT Obesity arises from intertwined and reciprocal diet‐microbiome‐host pathways that reshape energy balance, insulin sensitivity, and inflammation. This review synthesizes mechanistic links between microbial functions and metabolic control, charts lifestyle‐related lifecourse dynamics from birth to older age, examines how GLP‐1‐based therapies ...
Ioanna Panagiota Kalafati, David Krongauz, Alice Bosco, Antonio Noto, Cristina Piras, Maria Kafyra, Angelica Dessì, Matteo Mauri, Luigi Atzori, Adina Weinberger, Vassilios Fanos, George V. Dedoussis, on behalf of the BETTER4U consortium   +12 more
wiley   +1 more source

Tirzepatide-Associated Severe Hepatocellular Injury: A Case Report and Diagnostic Considerations. [PDF]

Diagnostics (Basel)
Kim DG, Yoo JJ, Kim SG, Kim YS.
europepmc   +1 more source

Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study. [PDF]

BMC Endocr Disord
Demircan F, Ozozan OV, Gozel N.
europepmc   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. [PDF]

J Am Heart Assoc
Wu JY, Lee KW, Kao CL, Hung KC, Yu T, Lin YM.   +5 more
europepmc   +1 more source